Zemcelpro (R) (dorocubicel), also known as UM171 Cell Therapy, is a novel personalized cryopreserved haematopoietic stem cell transplantation product containing two components, namely UM171-expanded ...

Please provide your email address to receive an email when new articles are posted on . Most patients with newly diagnosed high-risk myelodysplastic syndrome do not receive guideline-recommended ...

The phase 3 trial for high-risk MDS with RARA overexpression did not achieve its primary endpoint of CR rate. Tamibarotene-Vidaza treatment showed a 23.8% CR rate, not significantly different from the ...

Hematopoietic cell transplantation improved survival among high-risk genetic subgroups of patients with myelodysplastic syndrome, a recent study found. Allogeneic hematopoietic cell transplantation ...

Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. We all know that MDS is a cancer of the ...

Most patients with high-risk myelodysplastic syndromes (MDS) do not receive guideline-recommended treatment with hypomethylating agents (HMAs), according to results published in Blood Neoplasia. The ...

Azacitidine (Vidaza, Celgene) is standard treatment for patients with myelodysplastic syndrome (MDS) and will remain the treatment of choice — at least for now. A new study that tested two different ...

Evidence suggests that allogenic hematopoietic cell transplantation (HCT) improves overall survival in patients with myelodysplastic syndrome (MDS), a serious blood disorder, when compared with best ...

CEO, Dr Juho Jalkanen, talked with Proactive about the company’s planned €40 million rights offering and the next development ...

Integrating Social Needs Screening and Resource Referral Into Standard Ambulatory Oncology Care: A Quality Improvement Project Three hundred eighty-four patients received HCT (n = 260) or standard of ...